PIM1 expression is correlated with poor prognosis in DLBCL, NOS and the most common PIM1 mutations identified in patients with poor response to targeted therapy are G28D, L2V, and S97N. The gene discussed is PIM1; the disease is diffuse large B-cell lymphoma.